SDGR Schrodinger (SDGR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001490978
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
128
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $137.1K priced
What the filings say about SDGR
Insiders, 180 days
-$941.6K net sold
2 sellers · 67% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$756.2K
1 notice
Schrodinger insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Schrodinger, Inc. insiders sold a net $941.6K of stock across 104 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 5, 2026.
- The trade is 10.9% of the 91,555 shares held after it.
- No other insider sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Akinsanya Karen sold about $280.0K of SDGR under a 10b5-1 plan on Sep 17, 2026; 128 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 5, 2026.
- The trade is 30.9% of the 69,956 shares held after it.
- No other insider sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Akinsanya Karen sold about $648.0K of SDGR under a 10b5-1 plan on Sep 17, 2026, the largest insider sale at the company since 2023; 128 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 16, 2026.
- The trade is 1.7% of the 50,877 shares held after it.
- No other insider sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & CFO Jain Rachit sold about $13.6K of SDGR on Jul 16, 2026; 128 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Apr 16, 2026.
- The trade is 13.0% of the 330,824 shares held after it.
- 1 other insider sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Farid Ramy sold about $525.0K of SDGR on Apr 17, 2026; 1 other insider sold within 30 days and 128 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Mar 5, 2026.
- The trade is 13.0% of the 330,824 shares held after it.
- 1 other insider sold within 30 days.
- 128 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Farid Ramy sold about $530.2K of SDGR on Apr 16, 2026, the largest insider sale at the company since 2023; 1 other insider sold within 30 days and 128 funds added in the latest 13F quarter.104 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$941.6K over 180 days
-$928.0K over 90 days
below 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
128 funds bought in last quarter
more than 78% of Pharma & Biotech
Revenue
+23.3% year over year
more than 69% of Pharma & Biotech
Margin
-40.4% net margin
more than 52% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
18.1% of the float short (float per yahoo 2026-10-27) · 3.4 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SDGR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+11.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SDGR: institutional holders (13F)
13F holdings, latest reported quarter
10,521,724 sh
$171.0M
6,981,664 sh
$113.5M
6,400,000 sh
$104.0M
3,787,391 sh
$61.5M
2,706,143 sh
$44.0M
Congress trades in SDGR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SDGR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
KAREN OLUFUNMILYO AKINSANYA-AKIWUMI
Filed 2026-09-17
$756.2K
Jain Rachit
Filed 2026-07-16
$13.6K
Aklian Mannix Vartan
Filed 2026-07-01
$18.9K
SDGR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
TrueShares Technology, AI & Deep Learning ETF
$1.2M position · as of 2026-06-30
2.8%
ARK Genomic Revolution ETF
$30.9M position · as of 2026-07-31
2.0%
Global X HealthTech ETF
$225.2K position · as of 2026-05-31
0.9%
MFS New Discovery Fund
$18.4M position · as of 2026-05-31
0.9%
WesMark Small Company Fund
$1.3M position · as of 2026-06-30
0.7%
MFS New Discovery Series
$4.5M position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Ramy Farid
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.1M
$3.2M
$1.9M
-77%
+26%
2024
$4.4M
$667.0K
$2.3M
-76%
+1%
2023
$3.1M
$9.7M
$2.0M
-55%
-2%
2022
$3.9M
-$3.0M
$1.6M
-76%
-5%
2021
$8.5M
-$21.1M
$4.1M
-56%
-3%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $941.6K sold by insiders over 180 days, 128 funds added last quarter, $756.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
SDGR financials
Revenue growth
+23.3%
XBRL, annual
Net margin
-40.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$259.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SDGR
| FY Dec 2025 | $255.9M |
| FY Dec 2024 | $207.5M |
| FY Dec 2023 | $216.7M |
| FY Dec 2022 | $181.0M |
| FY Dec 2021 | $137.9M |
| Jun 2026 | $58.9M |
| Mar 2026 | $58.6M |
| Dec 2025 | $87.2M |
| Sep 2025 | $54.3M |
| Jun 2025 | $54.8M |
| Mar 2025 | $59.6M |
| Dec 2024 | $88.3M |
| Sep 2024 | $35.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-21.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM SDGR
| FY Dec 2025 | -40.4% |
| FY Dec 2024 | -90.2% |
| FY Dec 2023 | +18.8% |
| FY Dec 2022 | -82.4% |
| FY Dec 2021 | -73.4% |
| Jun 2026 | +10.1% |
| Mar 2026 | -102.5% |
| Dec 2025 | +37.3% |
| Sep 2025 | -60.4% |
| Jun 2025 | -78.8% |
| Mar 2025 | -100.4% |
| Dec 2024 | -45.5% |
| Sep 2024 | -108.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$130.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SDGR
| FY Dec 2025 | $12.5M |
| FY Dec 2024 | -$164.7M |
| FY Dec 2023 | -$150.1M |
| FY Dec 2022 | -$127.7M |
| FY Dec 2021 | -$77.8M |
| Jun 2026 | -$34.4M |
| Mar 2026 | -$17.3M |
| Dec 2025 | -$16.1M |
| Sep 2025 | -$62.4M |
| Jun 2025 | -$52.5M |
| Mar 2025 | $143.5M |
| Dec 2024 | -$32.0M |
| Sep 2024 | -$34.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity SDGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt SDGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-16.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SDGR
| FY Dec 2025 | -26.3% |
| FY Dec 2024 | -38.6% |
| FY Dec 2023 | +8.2% |
| FY Dec 2022 | -29.7% |
| FY Dec 2021 | -17.1% |
| Jun 2026 | -16.2% |
| Mar 2026 | -30.1% |
| Dec 2025 | -26.3% |
| Sep 2025 | -45.7% |
| Jun 2025 | -44.4% |
| Mar 2025 | -43.3% |
| Dec 2024 | -38.6% |
| Sep 2024 | -35.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-8.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SDGR
| FY Dec 2025 | -13.3% |
| FY Dec 2024 | -23.0% |
| FY Dec 2023 | +5.5% |
| FY Dec 2022 | -20.6% |
| FY Dec 2021 | -13.5% |
| Jun 2026 | -8.2% |
| Mar 2026 | -15.0% |
| Dec 2025 | -13.3% |
| Sep 2025 | -26.6% |
| Jun 2025 | -26.3% |
| Mar 2025 | -26.0% |
| Dec 2024 | -23.0% |
| Sep 2024 | -24.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SDGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-30.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SDGR
| FY Dec 2025 | -28.6% |
| FY Dec 2024 | -32.2% |
| FY Dec 2023 | -28.4% |
| FY Dec 2022 | -23.6% |
| FY Dec 2021 | -16.7% |
| Jun 2026 | -30.7% |
| Mar 2026 | -31.6% |
| Dec 2025 | -28.6% |
| Sep 2025 | -32.0% |
| Jun 2025 | -34.4% |
| Mar 2025 | -31.9% |
| Dec 2024 | -32.2% |
| Sep 2024 | -35.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SDGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 66.30x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value SDGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield SDGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SDGR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $255.9M | $207.5M | $216.7M | $181.0M |
| Gross profit | $142.6M | $132.1M | $140.7M | $101.0M |
| Operating income | -$166.9M | -$209.3M | -$177.4M | -$146.8M |
| Net income | -$103.3M | -$187.1M | $40.7M | -$149.2M |
| EPS (diluted) | -1.41 | -2.57 | 0.54 | -2.10 |
| Operating cash flow | $13.9M | -$157.4M | -$136.7M | -$119.7M |
| Cash | $230.5M | $147.3M | $155.3M | $90.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
SDGR Stock Sonar score 5/7 axes
Find similar shapesCompareSDGR ranks highest on growth (83rd percentile) and institutional and government (78th), and lowest on insider conviction (29th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SDGR filings, in plain words
Are Schrodinger insiders buying or selling SDGR?
In the 180 days to 2026-10-28, Schrodinger insiders were net sellers, a net $941.6K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of SDGR?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $756.2K of stock; the latest, by KAREN OLUFUNMILYO AKINSANYA-AKIWUMI, was filed 2026-09-17.
Read the full summary
In the 180 days to 2026-10-28, Schrodinger insiders were net sellers of SDGR, a net $941.6K across purchases and sales reported on Form 4 by 2 sellers. 67% of the 3 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $756.2K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
